In the case of hepatocellular carcinoma (HCC) patients, anti-PD-1, anti-PD-L1, and anti-CTLA-4 monoclonal antibodies are commonly used ICIs in clinical practice. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.